Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 11 | 2024 | 335 | 1.530 |
Why?
|
| Skin Neoplasms | 7 | 2024 | 405 | 0.780 |
Why?
|
| Neoplasms | 9 | 2025 | 1261 | 0.510 |
Why?
|
| Immunotherapy | 3 | 2025 | 237 | 0.500 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2024 | 202 | 0.460 |
Why?
|
| Indoles | 1 | 2013 | 102 | 0.410 |
Why?
|
| Sulfonamides | 1 | 2013 | 123 | 0.400 |
Why?
|
| Benzimidazoles | 2 | 2024 | 59 | 0.390 |
Why?
|
| Antineoplastic Agents | 3 | 2013 | 647 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 405 | 0.330 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2025 | 21 | 0.240 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 225 | 0.230 |
Why?
|
| Uveal Neoplasms | 1 | 2024 | 52 | 0.230 |
Why?
|
| After-Hours Care | 1 | 2023 | 8 | 0.220 |
Why?
|
| Paclitaxel | 1 | 2024 | 91 | 0.220 |
Why?
|
| Nervous System Diseases | 1 | 2025 | 105 | 0.220 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2013 | 53 | 0.200 |
Why?
|
| Microbiota | 1 | 2024 | 104 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2024 | 239 | 0.200 |
Why?
|
| T-Box Domain Proteins | 2 | 2012 | 40 | 0.190 |
Why?
|
| Neoplasm Staging | 3 | 2024 | 460 | 0.180 |
Why?
|
| Campylobacter Infections | 1 | 2020 | 4 | 0.180 |
Why?
|
| Oxadiazoles | 1 | 2020 | 7 | 0.180 |
Why?
|
| Hydroxamic Acids | 2 | 2009 | 27 | 0.160 |
Why?
|
| Mycophenolic Acid | 1 | 2019 | 32 | 0.160 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 31 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 3 | 2015 | 858 | 0.160 |
Why?
|
| Receptor, ErbB-2 | 2 | 2010 | 51 | 0.150 |
Why?
|
| ErbB Receptors | 2 | 2010 | 113 | 0.150 |
Why?
|
| Colitis | 1 | 2019 | 76 | 0.150 |
Why?
|
| Humans | 23 | 2025 | 60142 | 0.150 |
Why?
|
| Bacteria | 1 | 2020 | 278 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 157 | 0.140 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 196 | 0.140 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 346 | 0.140 |
Why?
|
| United Kingdom | 3 | 2024 | 70 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 171 | 0.130 |
Why?
|
| Diet | 1 | 2020 | 637 | 0.130 |
Why?
|
| Ipilimumab | 3 | 2022 | 10 | 0.120 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 48 | 0.120 |
Why?
|
| Aged | 10 | 2024 | 13584 | 0.110 |
Why?
|
| Middle Aged | 10 | 2024 | 16539 | 0.110 |
Why?
|
| POU Domain Factors | 1 | 2012 | 3 | 0.100 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 5197 | 0.100 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 17 | 0.100 |
Why?
|
| Cadherins | 1 | 2012 | 69 | 0.100 |
Why?
|
| Drug Design | 1 | 2013 | 144 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2013 | 345 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2012 | 306 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 256 | 0.090 |
Why?
|
| Adult | 9 | 2023 | 15988 | 0.090 |
Why?
|
| Quinazolines | 1 | 2010 | 22 | 0.090 |
Why?
|
| Retinoblastoma Protein | 1 | 2010 | 37 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 443 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 483 | 0.080 |
Why?
|
| Male | 10 | 2024 | 27975 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 3 | 2020 | 42 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2024 | 52 | 0.080 |
Why?
|
| Glycine | 1 | 2009 | 45 | 0.080 |
Why?
|
| Europe | 2 | 2023 | 184 | 0.080 |
Why?
|
| Aminopeptidases | 1 | 2009 | 28 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2008 | 31 | 0.080 |
Why?
|
| Female | 10 | 2024 | 31253 | 0.080 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2008 | 67 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2007 | 30 | 0.070 |
Why?
|
| Prognosis | 3 | 2019 | 1592 | 0.070 |
Why?
|
| Disease Progression | 3 | 2020 | 1054 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2012 | 2894 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2024 | 6140 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2023 | 2480 | 0.060 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 42 | 0.060 |
Why?
|
| Transcription, Genetic | 3 | 2012 | 848 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2024 | 5263 | 0.050 |
Why?
|
| Steroids | 1 | 2023 | 55 | 0.050 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2022 | 13 | 0.050 |
Why?
|
| Chemokine CCL8 | 1 | 2022 | 6 | 0.050 |
Why?
|
| Triage | 1 | 2023 | 111 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2023 | 197 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 103 | 0.050 |
Why?
|
| Animals | 3 | 2020 | 19771 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 248 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2362 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2023 | 147 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2022 | 309 | 0.050 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2020 | 5 | 0.040 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2020 | 17 | 0.040 |
Why?
|
| Proton Pump Inhibitors | 1 | 2020 | 38 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 170 | 0.040 |
Why?
|
| Prodrugs | 1 | 2020 | 32 | 0.040 |
Why?
|
| Incidence | 1 | 2023 | 1265 | 0.040 |
Why?
|
| Cognition | 1 | 2024 | 466 | 0.040 |
Why?
|
| Dysbiosis | 1 | 2020 | 56 | 0.040 |
Why?
|
| Length of Stay | 1 | 2023 | 781 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2020 | 119 | 0.040 |
Why?
|
| Spindle Apparatus | 1 | 2020 | 123 | 0.040 |
Why?
|
| Cetuximab | 1 | 2018 | 8 | 0.040 |
Why?
|
| Platinum | 1 | 2018 | 21 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2012 | 1384 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 238 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2020 | 249 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 435 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 1565 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 222 | 0.030 |
Why?
|
| Protein Binding | 2 | 2012 | 1566 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 600 | 0.030 |
Why?
|
| Hospitalization | 1 | 2023 | 1302 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1110 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 1039 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2015 | 74 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 737 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 558 | 0.030 |
Why?
|
| PAX3 Transcription Factor | 1 | 2012 | 13 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2012 | 60 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2012 | 209 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2012 | 91 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 168 | 0.020 |
Why?
|
| Melanocytes | 1 | 2012 | 78 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2019 | 3131 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 425 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 546 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2010 | 72 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2010 | 153 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 281 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 661 | 0.020 |
Why?
|
| Half-Life | 1 | 2009 | 70 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 111 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 665 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 943 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 63 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2101 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2010 | 336 | 0.020 |
Why?
|
| Growth Hormone | 1 | 2007 | 19 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 860 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2007 | 32 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 514 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 807 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 598 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Genes, erbB-2 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2007 | 14 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 1589 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 1983 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 113 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 793 | 0.020 |
Why?
|
| Cell Line | 1 | 2010 | 2017 | 0.020 |
Why?
|
| DNA | 1 | 2010 | 793 | 0.020 |
Why?
|
| Histones | 1 | 2008 | 464 | 0.020 |
Why?
|
| Insulin | 1 | 2007 | 689 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 10346 | 0.010 |
Why?
|